Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
José A. Guevara-Patiño, Manuel E. Engelhorn, Mary Jo Turk, Cailian Liu, Fei Duan, Gabrielle Rizzuto, Adam D. Cohen, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton
José A. Guevara-Patiño, Manuel E. Engelhorn, Mary Jo Turk, Cailian Liu, Fei Duan, Gabrielle Rizzuto, Adam D. Cohen, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton
View: Text | PDF
Research Article Oncology

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

  • Text
  • PDF
Abstract

T cells recognizing self antigens expressed by cancer cells are prevalent in the immune repertoire. However, activation of these autoreactive T cells is limited by weak signals that are incapable of fully priming naive T cells, creating a state of tolerance or ignorance. Even if T cell activation occurs, immunity can be further restricted by a dominant response directed at only a single epitope. Enhanced antigen presentation of multiple epitopes was investigated as a strategy to overcome these barriers. Specific point mutations that create altered peptide ligands were introduced into the gene encoding a nonimmunogenic tissue self antigen expressed by melanoma, tyrosinase-related protein-1 (Tyrp1). Deficient asparagine-linked glycosylation, which was caused by additional mutations, produced altered protein trafficking and fate that increased antigen processing. Immunization of mice with mutated Tyrp1 DNA elicited cross-reactive CD8+ T cell responses against multiple nonmutated epitopes of syngeneic Tyrp1 and against melanoma cells. These multispecific anti-Tyrp1 CD8+ T cell responses led to rejection of poorly immunogenic melanoma and prolonged survival when immunization was started after tumor challenge. These studies demonstrate how rationally designed DNA vaccines directed against self antigens for enhanced antigen processing and presentation reveal novel self epitopes and elicit multispecific T cell responses to nonimmunogenic, nonmutated self antigens, enhancing immunity against cancer self antigens.

Authors

José A. Guevara-Patiño, Manuel E. Engelhorn, Mary Jo Turk, Cailian Liu, Fei Duan, Gabrielle Rizzuto, Adam D. Cohen, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton

×

Figure 4

Immunization with optimized Tyrp1 rejects tumors and induces autoimmunity.

Options: View larger image (or click on image) Download as PowerPoint
Immunization with optimized Tyrp1 rejects tumors and induces autoimmunit...
C57BL/6 mice (15 per group) were immunized once weekly for 4 weeks (unless otherwise indicated in Methods) with Tyrp1, Tyrp1ee, Tyrp1ee/ng, Tyrp1ng, exo-Tyrp1, exo-Tyrp1ee, exo-Tyrp1ee/ng, and exotoxin A vector plus Tyrp1ee separately. Kaplan-Meier analyses are shown. (A) Immunization with exo-Tyrp1ee and -Tyrp1ee/ng protected ~75–90% (P < 0.01) of mice challenged with B16 melanoma cells, whereas Tyrp1ee immunization induced partial protection of ~40% (P < 0.05) and exo-Tyrp1ee/ng decreased protection (~10%). (B) Immunization with exo-Tyrp1ee DNA protected ~75% of mice and increased tumor protection compared with Tyrp1ee or exotoxin A plus Tyrp1ee (P < 0.05 versus Tyrp1). (C) Tyrp1ee/ng-induced autoimmunity manifested as coat hypopigmentation. Representative mice immunized with either Tyrp1ee/ng or Tyrp1 are shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts